Inhibition of phenylephrine-induced cardiomyocyte hypertrophy by activation of multiple adenosine receptor subtypes.
Gan
Xiaohong Tracey
XT
Department of Physiology and Pharmacology, University of Western Ontario, Medical Sciences Building, London, Ontario N6A 5C1, Canada.
Rajapurohitam
Venkatesh
V
Haist
James V
JV
Chidiac
Peter
P
Cook
Michael A
MA
Karmazyn
Morris
M
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D058907:Adenosine A1 Receptor Agonists; D058908:Adenosine A2 Receptor Agonists; D058909:Adenosine A3 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000009:adverse effects; D000818:Animals; D004347:Drug Interactions; D006984:Hypertrophy / Q000139:chemically induced*; D032383:Myocytes, Cardiac / Q000187:drug effects*; D010627:Phenethylamines / Q000494:pharmacology; D010656:Phenylephrine / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D043682:Receptor, Adenosine A1 / Q000502:physiology*; D043705:Receptor, Adenosine A2A / Q000502:physiology*; D043684:Receptor, Adenosine A3 / Q000502:physiology*
D058907:Adenosine A1 Receptor Agonists; D058908:Adenosine A2 Receptor Agonists; D058909:Adenosine A3 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D010627:Phenethylamines; D043682:Receptor, Adenosine A1; D043705:Receptor, Adenosine A2A; D043684:Receptor, Adenosine A3; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; C084956:N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; D010656:Phenylephrine; C048599:N(6)-cyclopentyladenosine; D000241:Adenosine